Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deep phenotyping and biomarker study in chronic inducible urticaria with omalizumab monitoring
NL-OMON56483Recruiting
- Sponsor
- Centre for Human Drug Research
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of omalizumab in chronic inducible urticaria (CIndU), Cold urticaria (CU), symptomatic dermatographism (SD) and 1 more (4 arms), sponsored by Centre for Human Drug Research. Primary endpoints: Blood-based biomarkers, Skin punch biopsy histology and 3 more. Started Jan 2024; status: recruiting.
02
Drugs
omalizumab
03
Conditions
chronic inducible urticaria (CIndU)Cold urticaria (CU)symptomatic dermatographism (SD)chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NL-OMON56483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56483.